|
|||||
|
|
Granulocyte growth factors: Achieving a consensus |
|
| Authors: | Boogaerts, M. Cavalli, F. Cortes-Funes, H. Gatell, J. M. Gianni, A. M. Khayat, D. Levy, Y. Link, H. |
| Affiliation: | 1University Hospital Leuven, Belgium 2 Osepedale San Giovanni, Bellinzona, Swizerland 3Hospital Universitario ‘12 de Octubre’ Madrid 4Hospital Clinic I Provincial Barcelona, Spain 5Istituto Nazionale Tumori Milano, Italy; 6Hôpital Pitié Salpètriere Paris 7Hôpital Henri Mondor Créteil Cedex, France 8Medizinische Hochshule Hannover, Germany |
| Abstract: | A consensus meeting held under the auspices of the EuropeanSchool of Oncology concluded that the use of granulocyte growthfactors is definitely indicated, or acceptable given existingevidence, in the following circumstances: to alleviate congenitalneutropenia; in the mobilisation of peripheral blood progenitorcells for autotransfusion; to encourage engraftment followingbone marrow transplantation and in cases of failed engraftment;to support continuationof ganciclovir anti-CMV therapy in certainpatients with AIDS, where the switch to foscarnet is contraindicatedor where toxicity to foscarnetdevelops. It was also agreed that there is an overwhelming need for carefullycontrolled clinical trials in a wide range of indications inwhich growth factor use may improve outcome. In the majorityof tumours, the possible benefit of dose optimisation and intensification,and therefore the role of growth factors in support of suchmeasures has still to be defined. Extramedullary toxicitiesmay in these instances become dose limiting. growth factors, neturopenia, peripheral blood, progenitor cells, bone marrow transplantation, AIDS |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |